# Proof-of-concept Trial of Apraglutide in Acute Graft Versus Host Disease (aGVHD)

> **NCT05415410** · PHASE2 · TERMINATED · sponsor: **VectivBio AG** · enrollment: 31 (actual)

## Conditions studied

- GVHD

## Interventions

- **DRUG:** Apraglutide

## Key facts

- **NCT ID:** NCT05415410
- **Lead sponsor:** VectivBio AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-05-25
- **Primary completion:** 2024-12-17
- **Final completion:** 2024-12-17
- **Target enrollment:** 31 (ACTUAL)
- **Why stopped:** Company decision
- **Last updated:** 2025-10-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05415410

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05415410, "Proof-of-concept Trial of Apraglutide in Acute Graft Versus Host Disease (aGVHD)". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05415410. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*